Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

ASTELLAS FARMA LDA

NIF 502540249
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €17,406,140 31 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €17,406,140 31 contracts
A2 · Late Publication €7,543,011,444 1,541 contracts
Contract published to BASE more than 10 days after the signing date
LOW €7,543,011,444 1,541 contracts
A5 · Threshold Splitting €8,645,097 38 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €8,645,097 38 contracts
A6 · Low Competition €2,996,519 28 contracts
Only one bidder participated in a competitive procedure
MEDIUM €2,996,519 28 contracts
A9 · Abnormal Price Reduction €9,136,952,664 653 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €9,136,952,664 653 contracts
C3 · Missing Mandatory Fields €8,086,995 41 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €8,086,995 41 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

166
€428,470,831
249
€417,372,943
55
€414,367,780
80
€404,546,691
22
€381,327,956
104
€381,137,980
26
€374,580,602
62
€373,018,895
19
€359,595,982
236
€350,867,378
63
€349,966,981
23
€335,053,171
18
€331,656,775
26
€327,454,836
12
€320,462,812
124
€272,332,829
154
€271,349,399
19
€269,977,703
28
€268,927,100
12
€267,768,845
Page 1 of 3 · 53 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 1 · 31 contracts

AQUISIÇAO URGENTE MEDICAMENTOS 41013425
PT · 12112243 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€58,702 2025-07-25
ENFORTUMAB VEDOTINA 20 MG PÓ SOL PERF IV
PT · 11411220 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€108,000 2025-03-07
VÁRIOS MEDICAMENTOS
PT · 11306751 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€43,704 2025-02-24
Aquisição medicamento tacrolimus 0,5mg_5mg _1mg_0,5mg ap comp
PT · 11718064 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€682,546 2025-02-18
Aquisição Medicamento enfortumab vedotina inj. 20mg iv_enfortumab vedotina inj. 30mg iv
PT · 11447840 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€135,000 2025-01-16
Enfortumab
PT · 11082658 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€108,000 2024-11-07
Fornecimento de substância ativa: Enfortumab vedotina 20mg e 30mg
PT · 10379471 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€445,500 2023-12-04
Fornecimento da substância ativa: Enfortumab vedotina 20mg e 30mg
PT · 10116650 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€76,500 2023-07-10
Medicamento Enfortumab Vedotina
PT · 10117215 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2023-06-29
Medicamento Tacrolimus ao abrigo do CPA 2021/6 dos SPMS
PT · 10155215 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€1,490,428 2023-05-03
Enfortumab vedotina 20 mg Pó Sol Perf IV
PT · 9888680 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€108,000 2023-01-27
AD-2020-162 - Ajuste Direto para a aquisição de bens para suprir necessidades, para as Instituições do SNS
PT · 7697980 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€13,711,769 2021-02-01
ANESTESICOS GERAIS E LOCAIS
PT · 3255114 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€158,394 2017-02-23
MEDICAMENTOS NEFRO
PT · 3221450 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€34,236 2017-02-06
Medicamentos do foro oncológico - com base no CPA 2013/6
PT · 2276080 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2015-10-29
Medicamentos anestésicos e relaxantes musculares
PT · 2293012 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2015-01-22
20Leuprorrelina 45 mg Pó sol inj Ser SC
PT · 1204728 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€5,613 2014-06-24
15Leuprorrelina 45 mg Pó sol inj Ser SC
PT · 1166758 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€5,868 2014-05-27
15Leuprorrelina 45 mg Pó sol inj Ser SC
PT · 1138183 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€5,868 2014-04-16
Com Base no CPA 2011_6
PT · 1168051 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2014-04-04
15Leuprorrelina 45 mg Pó sol inj Ser SC
PT · 1136322 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€5,868 2014-02-26
15Leuprorrelina 45 mg Pó sol inj Ser SC
PT · 1134678 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€5,868 2014-02-04
15 Leuprorrelina 45 mg Pó sol inj Ser SC
PT · 1134205 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€5,868 2014-01-14
Aquisição de Medicamentos vários
PT · 722735 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€66,000 2012-11-26
Aquisição de medicamentos vários
PT · 613868 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€66,000 2012-10-24
Aquisição de Medicamentos diversos
PT · 580338 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€66,000 2012-09-26
Aquisição de Medicamentos e Reagentes
PT · 574483 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€7,000 2012-09-19
10 seringas Leuprorrelina 45mg pó sol inj
PT · 560559 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€5,408 2012-08-17
Medicamentos antineoplásicos e imunomodulares ACSS
PT · 551840 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€0 2012-08-10
leucoprorrelina 22.5 solinj.
PT · 454398 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€0 2012-01-25
Tansulosina 0.4 mg comp.
PT · 496393 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2012-01-11
Overview
Total Value Won
€9,273,228,876
Contracts Won
2,183
Score 72430 · CRITICAL RISK
NIF
502540249
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • C.L. [P-c41c]
    Gerente
    since 2023-11-21
  • J.M. [P-507f]
    Gerente
    since 2024-06-28
  • R.I. [P-b4a3]
    Gerente
    since 2026-03-26
  • R.M. [P-6a6b]
    Gerente
    since 2016-09-27
  • R.M. [P-6a6b]
    Gerente
    since 2024-06-28
  • A.P. [P-d113]
    Sócio
    since 2015-04-10
  • A.P. [P-7a72]
    Sócio
    since 2015-04-10
  • A.G. [P-3e39]
    Gerente
    2011-06-17 → 2016-03-24
  • D.B. [P-b4bb]
    Gerente
    2016-04-06 → 2018-09-26
  • E.T. [P-f3f8]
    Gerente
    2016-02-22 → 2018-09-17
  • E.T. [P-f3f8]
    Gerente
    2021-01-15 → 2021-09-20
  • F.J. [P-4794]
    Gerente
    2016-04-06 → 2026-03-26
  • G.K. [P-c72f]
    Gerente
    2011-06-17 → 2016-02-22
  • H.Z. [P-e82d]
    Gerente
    2021-09-22 → 2023-10-30
  • J.H. [P-32ac]
    Gerente
    2016-02-22 → 2016-04-06
  • N.J. [P-1516]
    Gerente
    2011-06-17 → 2016-02-22
  • P.A. [P-dc72]
    Gerente
    until 2011-06-01
  • R.J. [P-8e74]
    Gerente
    2011-06-17 → 2016-09-05
  • Y.I. [P-0359]
    Gerente
    until 2015-04-07
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned